Durvalumab
英飞凡(Imfinzi)
A PD-L1 checkpoint inhibitor immunotherapy (AstraZeneca), standard after chemo-radiation in stage III lung cancer.
At a glance
China price
¥6,066 per (120mg/2.4mL); 500mg/10mL 18088 /
What this meansChecked against a primary or official source.
Source(s)
- https://www.himd.com/nivolumab/232263
Secondary source (media / community / commercial)
Last checked2026-09-08
Notes( HIMD 2026-03-18 ,-)
NRDL (national insurance)
NRDL status pending verification.
Regulatory status
NMPA approved; NRDL ——(2025),202611
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
Stage III NSCLC consolidation; extensive-stage SCLC; biliary tract cancer.
6066-1808810 | -:120mg/2.4mL≈6066/,500mg/10mL≈18088/60kg10mg/kg q3w2.5500mg,3.5-4.550;10,NHSA
Sources & verification
- https://www.himd.com/nivolumab/232263 — Secondary source (media / community / commercial)
Reader discussion
Public comments about Durvalumab. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.